Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Celltrion Inc (068270 KS)
Watchlist
462
Analysis
Health Care
•
South Korea
Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Celltrion Inc
•
09 Apr 2016 05:22
U.S. Remsima Expectations Too Optimistic
USFDA approved Celltrion’s Remsima, a biosimilar for JNJ’s Remicade, for use in treating rheumatoid arthritis, ulcerative colitis, Crohn’s, and...
Kemp Dolliver, CFA
201 Views
Share
bearish
•
Celltrion Inc
•
26 Mar 2016 21:33
Serious Questions to Consider
Our initial post on Celltrion focused on the fundamental risk of whether the company could meet the market's high expectations for its first...
Kemp Dolliver, CFA
202 Views
Share
bullish
•
Thematic (Sector/Industry)
•
29 Feb 2016 14:39
Share Buybacks in Korea - Top 9 Insights
In this report, we highlight 39 companies that have announced share buybacks in the past three months (Dec 2015 - Feb 2016) in Korea. We provide...
Douglas Kim
Follow
258 Views
Share
bullish
•
Thematic (Sector/Industry)
•
16 Feb 2016 00:59
2016 Major IPOs Pipeline in Korea - Part II
In our previous report - 2016 Major IPOs Pipeline in Korea, we identified 19 companies that are seeking to complete IPOs in Korea in 2016. In this...
Douglas Kim
Follow
225 Views
Share
bullish
•
Thematic (Sector/Industry)
•
12 Feb 2016 23:11
2016 Major IPOs Pipeline in Korea
This year appears to be an exciting year for IPOs in Korea, barring a dramatic downturn in global equities markets like the one we experienced in...
Douglas Kim
Follow
282 Views
Share
First
Previous
88
89
90
91
92
93
94
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.9
x